Keros Therapeutics (KROS) closed at $9.45 on November 5, 2026, down 12.7% from the previous close, on volume of 235,417 shares (30-day average 163,245).
Data as of November 5, 2026.
TipRanks (Fri, 6-Nov 9:01 AM ET)
Keros Therapeutics GAAP EPS of $0.70 beats by $1.72, revenue of $40M beats by $26.11M
Seeking Alpha News (Thu, 5-Nov 4:56 PM ET)
Keros Therapeutics Updates Corporate Presentation on Pipeline
TipRanks (Thu, 5-Nov 4:47 PM ET)
Keros Therapeutics Reports Recent Business Highlights and Third Quarter 2026 Financial Results
Globe Newswire (Thu, 5-Nov 4:01 PM ET)
Keros Therapeutics to Receive Additional Development Milestone Payment from Partner Takeda
Globe Newswire (Tue, 29-Sep 8:00 AM ET)
Globe Newswire (Mon, 28-Sep 8:00 AM ET)
Keros Therapeutics Announces $5 Million Share Repurchase Authorization
Globe Newswire (Tue, 8-Sep 4:01 PM ET)
Market Chameleon (Mon, 20-Oct 7:10 AM ET)
Keros Therapeutics Launches $194.4 Million Share Buyback—Key Facts for Investors
Market Chameleon (Mon, 20-Oct 5:09 AM ET)
Market Chameleon (Wed, 15-Oct 3:08 AM ET)
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
Keros Therapeutics trades on the NASDAQ stock market under the symbol KROS.
As of November 6, 2026, KROS stock price climbed to $9.71 with 58,320 million shares trading.
KROS has a beta of 1.82, meaning it tends to be more sensitive to market movements. KROS has a correlation of 0.16 to the broad based SPY ETF.
KROS has a market cap of $192.14 million. This is considered a Micro Cap stock.
Last quarter Keros Therapeutics reported $40 million in Revenue and $.70 earnings per share. This beat revenue expectation by $26 million and exceeded earnings estimates by $1.58.
In the last 3 years, KROS traded as high as $73.00 and as low as $9.12.
The top ETF exchange traded funds that KROS belongs to (by Net Assets): VTI, IWM, VXF, DFSV, IWN.
KROS has underperformed the market in the last year with a price return of -38.0% while the SPY ETF gained +10.2%. However, in the short term, KROS had mixed performance relative to the market. It has outperformed in the last 3 months, returning -2.9% vs -3.7% return in SPY. But in the last 2 weeks, KROS shares have been beat by the market, returning -14.4% compared to an SPY return of -3.3%.
KROS support price is $9.14 and resistance is $9.76 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that KROS shares will trade within this expected range on the day.
